NT5E
ENSG00000135318
Target class
Enzyme
Chromosome
6
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- NT5E
- Gene name
- 5'-nucleotidase ecto
- Gene symbol
- NT5E
- Previous gene symbols
- NT5
- Protein name
- 5'-nucleotidase (5'-NT) (EC 3.1.3.35) (EC 3.1.3.5) (EC 3.1.3.89) (EC 3.1.3.91) (EC 3.1.3.99) (5'-deoxynucleotidase) (Ecto-5'-nucleotidase) (IMP-specific 5'-nucleotidase) (Thymidylate 5'-phosphatase) (CD antigen CD73)
- CD73
- eN
- eNT
- CALJA
- Gene biotype
- Protein coding
- Gene family
- CD molecules|5'-nucleotidases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 191.92
- Tissue specificity (Gini)
- 0.582
- Tissue specificity (tau)
- 0.913
- KEGG gene identifiers
- hsa:4907
- Protein interaction confidence
- 0.845189
- Protein interaction partners
- 122
- R-HSA-196807
- R-HSA-73621
- R-HSA-74259
- R-HSA-9660826
- End position
- 85495791
- Start position
- 85449584
- Chromosome
- 6
- Strand
- Forward
- Cell membrane
- Lipid-anchor, GPI-anchor .
- Plasma membrane
- PubMed 2129526
- PubMed 24887587
- Tissue specificity (tau)
- 0.913016
- Expression inequality (Gini)
- 0.581534
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 191.92
- Cervix - Ectocervix
- 81.7
- Cervix - Endocervix
- 73.76
- Uterus
- 55.82
- Artery - Tibial
- 47.2
Expression in transcripts per million
- Cells - Cultured fibroblasts191.92
- Cervix - Ectocervix81.7
- Cervix - Endocervix73.76
- Uterus55.82
- Artery - Tibial47.2
- Artery - Aorta46.99
- Ovary45.53
- Vagina43.31
- Fallopian Tube37.27
- Artery - Coronary30.01
- Thyroid29.78
- Nerve - Tibial26.38
- Adipose - Subcutaneous23.04
- Colon - Sigmoid22.74
- Breast - Mammary Tissue19.38
- Bladder18.92
- Colon - Transverse17.56
- Adipose - Visceral (Omentum)15.74
- Esophagus - Gastroesophageal Junction15.3
- Small Intestine - Terminal Ileum14.28
- Prostate13.4
- Brain - Caudate (basal ganglia)12.93
- Esophagus - Muscularis12.57
- Liver11.03
- Pituitary10.88
And 29 more, listed on the interactive page.
- GO:0007159
- GO:0031214
- GO:0033198
- GO:0046034
- GO:0005886
- GO:0009986
- GO:0016020
- GO:0070062
- GO:0002953
- GO:0005515
- GO:0008253
- GO:0008270
- GO:0042802
Related records
Trials (29)
- A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
- A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
- A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
- A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
- An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
- COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
- Durvalumab and Oleclumab in Resectable PDAC
- Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
- IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
- MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
- Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Drugs (1)
- Oleclumab 5'-nucleotidase inhibitor